HUDDINGE, Sweden, April 30, 2003 (PRIMEZONE) -- Tripep AB (publ):
-- Planned cost reductions have been implemented, resulting in a
more than 50 per cent cut, without effecting R&D
-- Loss for the period -4.8 (-11.2)
-- R&D costs for the period 2.7 (2.8)
-- Research focusing on MetaboliteX, GPG(R)'s antiviral metabolite,
is continuing.
-- Discussions are under way with several partners concerning the
consolidation of operations through acquisitions.
-- The AGM adopted a buy-back programme whereby shareholders are
being offered the chance to sell one share in ten for SEK 30.
-- The AGM also decided to issue a maximum of 750,000 debt
instruments with detachable warrants.
For more information, please contact: Johan Ihre, President and CEO Tel.: +46 8 449 84 80 mobile phone: +46 707 33 44 25 E-mail: johan.ihre@tripep.se or Anders Vahlne, VP, Head of Research Tel.: +46 8 5858 1313 mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@labmed.ki.se Web site: www.tripep.se
Tripep is a biotechnology research company that develops andcommercialises candidate drugs based on patented technologies. Its mainfocuses are:
- research and development of a potential HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and Hepatitis C, and - the RAS (R) technology platform.
For more details of the company's technologies, please refer to thecompany's web site at www.tripep.se
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/04/30/20030430BIT00180/wkr0001.doc
The full report
http://www.waymaker.net/bitonline/2003/04/30/20030430BIT00180/wkr0002.pdf